Investigational drug · Phase 3
ULO
Also called: MK-8507, Ulonivirine, MK-8591B
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Human Immunodeficiency Virus Type 1 (HIV-1) Infection, HIV-1 Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "ULO"
First trial start
2021
Mar 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ULO", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- HIV-1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ULO" as an intervention, largest first.
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07266831 · 570 participants (planned) · Start Dec 18, 2025 · Primary completion Feb 1, 2029
Drug: ISL; ULO and 4 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 56 sites in all
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06891066 · 150 participants (planned) · Start Apr 14, 2025 · Primary completion Aug 10, 2027
Drug: ISL; ULO and 1 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: San Francisco, California; West Hollywood, California; Washington D.C., District of Columbia · 23 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07305831 · 62 participants · Start Jan 22, 2026 · Primary completion Apr 9, 2026
Drug: Ulonivirine; Moxifloxacin and 2 more · For: Healthy
Sites: San Antonio, Texas
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07334886 · 8 participants · Start Sep 17, 2025 · Primary completion Nov 11, 2025
Drug: [14C]Ulonivirine · For: Healthy
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV.
Nussbaum JC, Pham MM, Vargo R, et al. · Antimicrob Agents Chemother 2026
- An open-label, Phase 1 study to evaluate the drug-drug interaction between ulonivirine and the combined oral contraceptive levonorgestrel/ethinyl estradiol in female participants without HIV.
Robinson M, Gillespie G, Kandala B, et al. · Antimicrob Agents Chemother 2026
- A novel design of a hybrid hydrogel skin scaffold made from modified PVA/urea oligomer, incorporating protein and polysaccharide.
Dehghan Manshadi F, Sharzehee M, Mirjalili SA · J Biomater Sci Polym Ed 2026
- A Technical Feasibility Study of the Recovery of Used Lubricant Oil Using Ceramic Ultrafiltration Membranes.
Mohamed M, Vandezande P, Buekenhoudt A · Membranes (Basel) 2026
- Slower Progression Rates in Lower Limb-Onset ALS.
Shovman Y, Lerner Y, Gotkine M · J Clin Med 2026
- Effects of ultralow oxygen treatments at low temperature on survival of spotted wing drosophila, Drosophila suzukii (Diptera: Drosophilidae), in blueberries and sweet cherries.
Liu YB · J Econ Entomol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.